CMPX Stock — Compass Therapeutics Inc.: Cash, EV, Pipeline

What they do

We are a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Our scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Our pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response.

Source: 10-K FY2025 via SEC EDGAR

Share price

$0.76

Market cap

$136.7M

Cash

$179.9M

Enterprise value

-$43.2M

Balance sheet

Cash	$179.9M
Debt	$0.0M
Net cash	$179.9M
Enterprise value	-$43.2M
Basic shares	180.1M shares
Fully diluted shares	212.1M shares
Fully diluted market cap	$161.2M
Cash per share	$1.00
Quarterly burn	$14.7M
Cash runway	12.2 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

180.1M

Pre-funded warrants

6.7M

Options

23.7M

RSUs

1.6M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.0M

FDSO

212.1M

Cap table as of 2026-06-30.

Price history

Loading CMPX daily closes…

Loading price history…

Next catalyst

CTX-10726 · Est. Nov 15, 2026 · quarter midpoint · guided Now

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Nov 15, 2026 Now quarter midpoint	CTX-10726 Phase 1 study (initial clinical data)	Phase 1	Not disclosed	Q4 2026
GUIDEDEst. Nov 15, 2026 Now quarter midpoint	CTX-8371 Phase 1 cohort expansions (additional data)	Phase 1	Not disclosed	Q4 2026

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Tovecimig

Phase 2/3 · Active Modality: Bispecific antibody

Aliases CTX-009

Target DLL4 x VEGF-A

Partnerships ABL Bio (Nov 2018): exclusive global license excluding South Korea; jointly developed; ABL Bio responsible through end of Phase 1; eligible for up to $96M development/regulatory + $303M commercial milestones (oncology), tiered single-digit royalties

Indications

Biliary tract cancer (BTC), 2L, + paclitaxel (Phase 2/3)
BTC, 1L, investigator-sponsored (+ gemcitabine/cisplatin/durvalumab) (Phase 2/3)
Colorectal cancer, 3L/4L monotherapy (Phase 2)

Catalysts

— Q3 2026
— 2026

Status note COMPANION-002 Phase 2/3 trial in second-line biliary tract cancer (with paclitaxel) completed; survival and safety data announced April 2026.

CTX-471

Phase 1 · Active Modality: Agonistic antibody

Target CD137 (4-1BB)

Indications

Solid tumors incl. melanoma, SCLC, mesothelioma; Phase 2 basket in NCAM+ tumors planned (Phase 1)

Status note CD137 (4-1BB) agonist; Phase 1 ongoing.

CTX-8371

Phase 1 · Active Modality: Bispecific antibody

Target PD-1 x PD-L1

Indications

TNBC, Hodgkin lymphoma, NSCLC (metastatic/locally advanced) (Phase 1)

Catalysts

— Q4 2026

Status note First-in-human Phase 1 ongoing.

CTX-10726

Phase 1 · Active Modality: Bispecific antibody

Target PD-1 x VEGF-A

Indications

RCC, gastroesophageal, HCC, endometrial (locally advanced/metastatic) (Phase 1)

Catalysts

— 2026 (Q4)

Status note IND cleared early 2026; Phase 1 dose escalation underway.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	CTX-009
Lead indication	Biliary Tract Cancer
Lead phase	Phase 3
Active trials	0
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06548412	Phase 2	Recruiting	Collaborator	M.D. Anderson Cancer Center	—	Metastatic Biliary Tract Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for M.D. Anderson Cancer Center on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Tang Capital Partners	17,990,782	+1,199,973	1.79%	2026-08-14
OrbiMed Advisors	15,219,994	no change	0.63%	2026-08-14
Vivo Capital	7,757,060	-1,788,406	1.55%	2026-08-14
ADAR1 Capital Management	122,132	-16,868	0.01%	2026-08-14
Ikarian Capital	18,000	no change	0.01%	2026-08-14
RTW Investments	0	-4,186,599	0.00%	2026-08-14
Braidwell LP	0	-1,965,106	0.00%	2026-08-14
Logos Global Management	0	-3,150,000	0.00%	2026-08-14
Deerfield Management	0	-3,606,000	0.00%	2026-08-14
BVF Partners	0	-7,764,842	0.00%	2026-08-14
Great Point Partners	0	-1,350,000	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

CMPX — Compass Therapeutics Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

CMPX — Compass Therapeutics Inc.